|
|
|
|
 |
|  =Subscribers Only |
Get Four
|
|
 JUNE 11, 2004 The Bloom Is Off the ASCO Rose The annual cancer confab is over, and once again, so is investors' euphoria over possible breakthroughs  MAY 20, 2004 Statins in Aisle 7? Following Britain's lead, the FDA could soon approve the popular cholesterol-lowering medicines as over-the-counter remedies MAY 5, 2004 A Cancer Drug Under a Cloud Several troubling but inconclusive studies suggest that EPO, a huge earner for Amgen and J&J, might actually lower survival rates APRIL 29, 2004 Bigger Than Depression? Once associated mainly with hyper kids, attention deficit disorder is now widely diagnosed in adults. But drugs aren't the only answer APRIL 8, 2004 Has Obesity Met Its Match? The French pharma Sanofi is getting positive results so far with a drug that suppresses appetite. And it may have cardiac benefits, too MARCH 26, 2004 Angiotech's Drug-Coated Pipeline The Canadian outfit had its first hit with Taxus stents, licensed to Boston Scientific. Now, it's working to build on that success MARCH 15, 2004 A Risky Bet on Antibiotics? Small companies are licensing promising products rather than developing them from scratch. That may do little for profits and less for science MARCH 5, 2004 Acambis' Springboard: Smallpox The little biotech has done well supplying a vaccine to the U.S. CEO Gordon Cameron discusses how it plans to sustain its success FEBRUARY 25, 2004 Flu Vaccines for Everyone? If Uncle Sam made shots universal, a stabilized vaccine industry might be ready for the killer virus doctors have long feared FEBRUARY 20, 2004 Feds to Biotech: No More Fibbing! A little-noted change in drug-approval procedures is a step toward avoiding more ImClone-style stock scandals FEBRUARY 6, 2004 "Good" Cholesterol: Great for Kos The tiny drugmaker has been on a tear lately, thanks to its HDL-boosting drugs. CEO Adrian Adams talks about some challenges ahead JANUARY 5, 2004 What's Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D, mergers, and the FDA's changing role DECEMBER 29, 2003 A Happy Pill for Some Biotechs Analysts predict 2003's rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers DECEMBER 4, 2003 TB: Battling an Old Foe's Resurgence Foundations and drug companies are finding fresh ways to fight tuberculosis, a deadly disease given new life by the AIDS epidemic OCTOBER 24, 2003 Seeking a Prescription for Biogenerics No U.S. laws allow for generic versions of off-patent biotech medicines. Several forces are now working to change that OCTOBER 16, 2003 Cancer Drugs That Keep Survivors Going A new class of maintenance therapies with low side effects is showing promise in keeping patients from suffering relapses OCTOBER 9, 2003 Superpills with a One-Two Punch Drugmakers are hoping that pills packing a combination of medications can do a lot for patients -- and even more to revitalize revenues SEPTEMBER 24, 2003 Thalidomide's Surprising Act IV The notorious drug now shows promise of being an effective cancer fighter, and its noxious side effects can be largely eliminated AUGUST 18, 2003 On the Twisting Trail of Cancer Vaccines While success has eluded huge drug companies and small biotechs so far, scientists now have a better idea of what might work JULY 25, 2003 Good News about "Good" Cholesterol A variety of new drugs that boost HDL cholesterol levels or enhance HDL's effectiveness are generating extremely promising results JUNE 26, 2003 BIO 2003: Back to the Future A sense of optimism that has been sorely lacking in recent years resurfaced -- with caveats -- at the biotech industry's latest big confab JUNE 5, 2003 Toward a Safer Blood Supply John Barr, president and CEO of Vitex, says his new wash treatment can help remove contaminants such as viruses from blood cells MAY 8, 2003 The New Face of Anti-Aging Treatments Products coming to market could soon be adding some worry lines to the nonsurgical cosmetic-treatment leader, Botox APRIL 24, 2003 Using Teamwork to Tackle Disease DNA research pioneer Dr. Leroy Hood is now assembling a group of experts in different scientific fields to investigate systems biology MARCH 6, 2003 Biogen: No More One-Hit Wonder? CEO James Mullen talks about Amevive, the new psoriasis treatment that could be the first step to a diversified product line FEBRUARY 28, 2003 HGS's Haseltine: "We're Batting .800" A giant of the biotech industry says his company's genomic approach to developing drugs sets it apart from the pack DECEMBER 13, 2002 Biotechs Adopt the Orphan-Drug Market New treatments for rare disorders are producing both health and wealth -- but only for outfits that win FDA-sanctioned monopolies NOVEMBER 20, 2002 Betting on Biotech's Recuperation InvestBio Opportunity Fund believes the sector is ready for a rebound. Co-manager Libbe Englander explains how she's playing that hunch OCTOBER 10, 2002 How Merck Is Treating the Third World CEO Ray Gilmartin says the drugmaker's experience fighting river blindness can be applied to AIDS but that the industry can't do it alone SEPTEMBER 18, 2002 Amgen vs. J&J: Will It Ever End? The drugmakers' long-running feud over an anemia drug is in an arbitrator's hands, but that doesn't mean it's almost over SEPTEMBER 6, 2002 Why Merck Stands Alone Its basic-research VP explains why the drugmaking giant isn't looking to mergers to fuel growth AUGUST 9, 2002 A New Breed of Microbe Hunters There's a quiet urgency to smallpox-vaccine producer Acambis' other research: Defeat West Nile-type viruses before they turn up in the West JULY 25, 2002 Good News about HRT -- for Investors Controversy over Prempro has battered Wyeth's stock, which could make the shares a good buy for the long term JULY 18, 2002 A Hard Road to New Wonder Drugs With few potential blockbusters in its pipeline, Big Pharma is mounting a costly quest on the very edge of the scientific frontier MAY 23, 2002 Freedom from the Menstrual Cycle? Barr Labs is testing a new contraceptive pill that could all but banish monthly bleeding and open new lifestyle options for women MAY 16, 2002 Biogen Could Use This Shot in the Arm The biotech's promising treatment for psoriasis could boost its stock if the FDA approves the drug -- and that's a mighty big if APRIL 4, 2002 Getting Serious about Stopping STDs Diseases such as herpes and hepatitis affect millions of people. Now, several companies are racing for vaccines and treatments MARCH 21, 2002 Schering Puts on a Marketing Clinic As allergy drug Claritin goes over-the-counter, the drugmaker is pulling out the stops to pitch its successor, Clarinex MARCH 14, 2002 Food as a Cancer Therapy Researchers are renewing their quest to find links between diet and the disease that'll claim more than 500,000 American lives this year MARCH 7, 2002 A Shock to Lilly's System? Xigris, the drugmaker's new sepsis treatment, was supposed to help cover sales of Prozac lost to generics. It's falling far short MARCH 1, 2002 Celera: A Biotech That Needs a Boost The onetime genomics highflier has to replace departed founder Craig Venter and ramp up its drug-development unit -- fast FEBRUARY 14, 2002 Lessons from ImClone's Trial -- and Error Fast-lane tests led the FDA to reject a much-hyped cancer drug, and the stock tumbled -- a reminder of the peculiar perils biotech investors face JANUARY 25, 2002 Big Trouble in Biotech City? Don't count on it. Despite the slew of bad news, Big Pharma's need for new drugs is just one of many fuels for the industry JANUARY 17, 2002 Is This Poison a Tonic for Investors? A neurotoxin that banishes wrinkles, Botox is awaiting approval for cosmetic use. If that happens, Allergan could have the Viagra of 2002 JANUARY 10, 2002 Biotech's Single-Minded Killers Pay Off Monoclonal antibodies zero in on exactly the cells that need attacking. The companies developing them could make a killing, too DECEMBER 13, 2001 Rookie Drugs with Big-League Hopes Schering-Plough, Bristol-Myers, and Merck are each counting on a new remedy in 2002 to lift them out of 2001's slump NOVEMBER 30, 2001 Toward a Sensible Stem-Cell Policy Dismissed by some researchers as a stunt, the cloning of a human embryo has nevertheless rekindled a bitter debate. Here's a solution NOVEMBER 2, 2001 If Flu Vaccine Is In Such Short Supply... ...What does it mean for the effort to crank out anthrax and smallpox vaccines? The quick answer: Nothing good OCTOBER 25, 2001 Smallpox: "We Eradicated It Before..." Vaccine expert Lance Gordon talks about the history of the war on that scourge and what threats are worth worrying about OCTOBER 19, 2001 A Vexing Fact about Vaccines There's no way to know if a major inoculation campaign would be effective until the unthinkable actually happens View Next Page | The Biotech Beat Archive | |
|
Copyright by The McGraw-Hill Companies Inc. All rights reserved.